Genovis Launches New Enzyme Product

Genovis is launching a further development of GingisKHAN® that will be marketed under the name GingisKHAN®Fab kit. The product will be presented at the conference Antibody Engineering & Therapeutics in San Diego next week.

The GingisKHAN®Fab kit is a further development of the product GingisKHAN®,, which rapidly and specifically splits antibodies (IgG1) into Fab and Fc fragments. With the GingisKHAN®Fab kit, the customer can quickly and easily obtain intact Fab fragments with the right quality to be used further in the analysis.

Today, about 80 percent of all antibody-based drugs are based on IgG1 molecules, human immunoglobulin of subclass 1, which is also the most common antibody in the natural composition of human antibodies.

“The GingisKHAN®Fab kit is the basis for expanding our product portfolio toward new business areas, mainly in the biopharma industry. Our existing products are mainly used in mass spectrometry, but now we are broadening usage toward other analysis technologies. The GingisKHAN®Fab kit improves the quality and yield of the fragments that the customer generates and we have also simplified processing and reduced the time by more than 75 percent compared with currently available technologies on the market,” says Fredrik Olsson, CEO of Genovis.

For more information about the GingisKHAN®Fab kit: www.genovis.com/gingiskhan-fabkit

GingisKHAN® is a registered EU trademark

For more information, please contact: Fredrik Olsson, CEO, Genovis AB Tel: 0046 (0)46 -101233 fredrik.olsson@genovis.com

ABOUT GENOVIS

Genovis’ business concept is to offer customers in the pharmaceutical and medical device industries tools that facilitate and save time in the development of new treatment methods and diagnostics. Today Genovis sells several enzyme products known as SmartEnzymes all over the world in innovative product formats that facilitate development and quality control of biological drugs.

The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc. (USA).

Back to news